Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
about
To affinity and beyond: harnessing the T cell receptor for cancer immunotherapyIpilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.Inhibitory receptors as targets for cancer immunotherapyImmune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.Skin cancer in kidney transplant recipients.Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.Ipilimumab-induced hypophysitis: review of the literature.Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma.Acute Inflammatory Demyelinating Polyneuroradiculopathy with Ipilimumab in Metastatic Melanoma: A Case Report and Review of Literature.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis.Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis.Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination.Humanized mice as a model for aberrant responses in human T cell immunotherapy.Bilateral uveitis and macular edema induced by Nivolumab: a case report.Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.Identifying and managing the adverse effects of immune checkpoint blockade.Cell division cycle-associated protein 1 as a new melanoma-associated antigen
P2860
Q27008423-49E6151B-5A3B-442C-9E2E-91756C6DE8A7Q33591598-CF40E51F-9488-4830-A497-8C8A450BC5DDQ34000700-B5ADF523-EB4B-4321-A1B3-B505272ECBA7Q34558043-5E71F021-4094-4F4D-9E54-FFE641A88F02Q35783412-81E26A23-27B1-416B-9072-FA99145D2B80Q35995373-9B691C77-38F5-42A5-8F1C-B8BDB18151E5Q36173638-46A25A52-57B1-463A-B41A-B744E82D965BQ37131014-92DF2B4A-54BD-484F-8817-74196F78B38CQ38210273-8CB52EF8-7EAD-42E4-B696-8FC1C39B57C9Q38373891-A3CD76C8-CC1C-450E-A66A-7307B71F6E0AQ38469194-A1ED6F72-2CE8-4BEC-A920-717F687000B2Q38595251-0DC1A9CC-54FB-4F19-BD05-BE0CACF43A22Q38687208-5086DF7D-7667-4BC3-B1C7-57EB928F97ECQ38783026-09A315B2-8E1C-4DE0-A8E8-977A43B320E4Q38884560-7C1C7D7A-7A35-42DF-9512-DEF776760C47Q39004691-C6D92E2D-29B3-441A-A221-B8361E04ACD5Q39148284-6FDE9528-4334-4EBB-8B05-18B0526EB1FAQ40340021-6FE05A9D-4144-40E4-A271-DB4727381674Q40788906-69FB259A-CEC4-4413-BE6C-4B3B08A6C3D8Q41816196-8B0FF2FC-4579-4AE1-8BF5-40170E6173C8Q47098876-8FA1E238-BF1B-44F0-BF14-8BC140508A1FQ55110249-7B554C7E-4F17-4A61-96AC-452EEFD04600Q55409972-472EFEE3-47F4-4980-9005-8656A182033DQ57719088-79355921-608A-4417-9EA8-F037846E505B
P2860
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
@en
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
@nl
type
label
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
@en
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
@nl
prefLabel
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
@en
Ipilimumab in the treatment of metastatic melanoma: management of adverse events.
@nl
P2093
P2860
P356
P1476
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
@en
P2093
Celeste Fusciello
Chiara Carlomagno
Giuseppina Della Vittoria Scarpati
Soldano Ferrone
Stefano Pepe
P2860
P304
P356
10.2147/OTT.S57335
P407
P577
2014-02-19T00:00:00Z